Autonomix Medical (NASDAQ:AMIX) Issues Quarterly Earnings Results

Autonomix Medical (NASDAQ:AMIX) released its earnings results on Tuesday. The company reported ($2.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.62) by $0.11, FiscalAI reports.

Autonomix Medical Price Performance

NASDAQ AMIX traded up $0.15 during trading hours on Tuesday, hitting $1.85. The company’s stock had a trading volume of 62,744,642 shares, compared to its average volume of 1,638,157. The company has a market cap of $1.80 million, a P/E ratio of -0.05 and a beta of -0.70. The company’s 50 day simple moving average is $3.32 and its two-hundred day simple moving average is $6.56. Autonomix Medical has a 12 month low of $1.46 and a 12 month high of $32.55.

Wall Street Analyst Weigh In

A number of brokerages have commented on AMIX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Autonomix Medical in a research report on Monday, October 26th. Wall Street Zen raised shares of Autonomix Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 3rd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $42.00.

Autonomix Medical Company Profile

Autonomix Medical, Inc is a medical device company developing catheter-based technologies for the detection and treatment of conditions involving the peripheral nervous system. The company’s platform is designed to identify neural signals in real time, with the goal of helping physicians locate and selectively treat targeted nerves during minimally invasive procedures.

Autonomix’s lead development program is focused on pain associated with pancreatic cancer. Its technology is intended to support targeted nerve ablation, potentially offering an alternative approach for managing pain while reducing the need for more extensive procedures.